ExoMind™ TMS therapy
FDA-cleared TMS for major depressive disorder, with possible insurance coverage subject to eligibility and insurance approval. Accelerated off-label ExoMind: self-pay, with financing options that may be available for eligible patients.
In South Florida
ExoMind™ · Assertive Comprehensive Care • South Florida
ExoMind TMS:
Two Treatment Pathways
ACC offers two separate ExoMind pathways: FDA-cleared TMS for major depressive disorder (MDD), which may be covered by insurance for eligible patients, and personalized accelerated off-label protocols offered as self-pay services.
Insurance coverage depends on clinical eligibility, plan requirements, and final insurance approval. Coverage is not guaranteed. Financing options may be available for eligible self-pay patients, subject to approval, eligibility, and the financing provider’s terms.
Psychiatric Medical Oversight
Psychiatric Supervised
FDA-Cleared MDD TMS
BTL-699 · K260691
CareCredit
Health & wellness credit card
Zero Downtime
Drive yourself home
English & Spanish
Bilingual care team
ExoMind™ Clinical Summary
FDA-Cleared MDD TMS
Device: BTL EXOMIND TMS System, model BTL-699
FDA 510(k): K260691
FDA clearance decision date: August 23, 2026
Session duration at ACC: Approximately 18–18:45 minutes per session.
Treatment course: Up to 36 sessions, depending on the prescribed treatment course and clinical needs.
Insurance: May be covered by medical insurance for eligible patients.
Coverage depends on plan-specific clinical criteria, medical necessity, benefits, prior authorization when required, and final insurance approval. Coverage is not guaranteed.
TeleHealth
All of florida
Accelerated ExoMind / Off-Label
Accelerated ExoMind
Personalized accelerated ExoMind protocols are offered as a separate self-pay treatment pathway.
• Individualized off-label protocols.
• Generally 6–8 sessions.
• Approximately 24–30 minutes per session.
• Self-pay / out-of-pocket.
These services are separate from the FDA-cleared MDD insurance pathway. Off-label or wellness services should not be considered covered by insurance unless specifically authorized by the patient’s plan.
Financing options may be available for eligible patients interested in self-pay ExoMind services. Financing is subject to approval, eligibility, and the terms of the applicable financing provider.
Financing availability, approval, rates, terms, and monthly payment amounts are determined by the financing provider and may vary by applicant.
The Science Behind ExoMind™
Precision Magnetic
Brain Stimulation
ExoMind™ uses transcranial magnetic stimulation (TMS) technology to deliver brief, precisely targeted magnetic pulses to specific brain regions involved in mood regulation, cognition, and executive functioning. Unlike medications that circulate throughout the body, TMS stimulates targeted neural networks without the need for anesthesia or sedation.
Unlike antidepressants that flood the entire body systemically, ExoMind™ TMS targets only the specific neural circuit governing mood regulation. Because ExoMind™ directly targets specific brain circuits rather than acting systemically, it offers a different therapeutic approach that may benefit appropriately selected patients, including those who have not achieved adequate improvement with traditional treatments.
Repeated stimulation promotes neuroplasticity the brain’s ability to strengthen and reorganize neural networks over time. These changes may support improvements in mood regulation, cognitive function, emotional resilience, and overall brain performance.
Comprehensive Psychiatric Evaluation
Every patient undergoes a comprehensive psychiatric evaluation to determine whether ExoMind™ is appropriate and to develop an individualized treatment plan.
Personalized Protocol
Treatment parameters—including stimulation location, intensity, and frequency—are individualized based on your clinical presentation, goals, and response to therapy.
Comfortable Treatment Sessions
Sessions are scheduled according to your prescribed treatment plan. Session duration varies by protocol. You remain awake throughout treatment, and your provider will explain what to expect before you begin.
Progress Monitoring
Throughout treatment we continually monitor symptom improvement, tolerability, and functional outcomes, making individualized adjustments when clinically appropriate.
“TMS is one of the most significant advances in depression treatment in decades.”
— Clinical Psychiatry Reports, 2023
What Does ExoMind™ Feel Like?
- Mild scalp muscle contractions
- Fully awake throughout treatment
- No anesthesia
- No sedation
- No recovery period
- Return to work immediately
Clinical Evidence
The Data Behind Every Protocol
ExoMind™ TMS is not an experimental treatment. It is one of the most extensively studied neuromodulation therapies in modern psychiatry, supported by decades of clinical research involving thousands of patients worldwide. BTL sponsored clinical data reported that:
74% reported feeling happier after treatment.
91% of participants found treatment sessions comfortable.
90% reported improvements in overall well-being.
90% reported improvement in depression and anxiety symptoms.
77% reported better mood and energy.
Source: BTL internal clinical data.
50–60%
Clinical Response Rate
Patients experiencing meaningful, measurable reduction in depressive symptoms following a full 36-session TMS course.
PEER-REVIEWED RESEARCH
Full Remission Rate
Patients achieving complete remission from depressive symptoms — essentially no symptoms remaining after treatment.
PUBLISHED META-ANALYSIS
FDA Clearance Year
TMS has been FDA-cleared for major depressive disorder since 2008 — over 15 years of established post-market safety data.
U.S. FDA
36
Standard Session Protocol
The clinically validated course involves 36 sessions over 6–9 weeks, with maintenance sessions available as needed.
CLINICAL PROTOCOL
FDA Cleared Indications
TMS holds two separate FDA clearances — for major depression (2008) and obsessive-compulsive disorder (Deep TMS).
FDA INDICATIONS
Serious Adverse Event Rate
Serious adverse events (seizure risk) occur in under 1% of cases comparable to rates seen with antidepressant medications.
SAFETY REGISTRY DATA
What ExoMind™ Delivers
Eight Clinical
Transformations
Neurostimulation creates measurable, lasting change across multiple domains of mental health and cognitive function not just symptom suppression, but genuine neural recovery.
Each benefit below has been observed in clinical populations and is grounded in the neuroscience of what TMS does to prefrontal and limbic circuitry over a sustained treatment course.
How ExoMind™ Differs from Medication
Antidepressants work systemically affecting the entire body. ExoMind™ TMS works locally, precisely activating the underperforming neural circuits responsible for mood without touching the rest of your biology. That specificity is why treatment-resistant patients often respond.
Improved Mood
Restores emotional balance through direct stimulation of the mood-governing prefrontal circuits that become underactive in depression.
Reduced Anxiety
Modulates hyperactive fear networks in the amygdala, producing a calmer, more composed baseline emotional state.
Mental Clarity & Focus
Enhanced executive functioning, sharper attention, and reduced cognitive fog measurable improvements in how you think and process.
Improved Sleep
Neural recalibration supports healthier sleep architecture, deeper rest cycles, and more consistent sleep-wake patterns.
Emotional Regulation
Better management of emotional reactivity, reduced interpersonal volatility, and more stable moment-to-moment experience.
Motivation & Drive
The anhedonia and inertia of depression lift patients regain initiative, engagement with life, and capacity for reward and pleasure.
Reduced Impulsivity
Strengthened prefrontal inhibitory control supports healthier decision-making and better self-regulation.
Stress Resilience
A more adaptive, regulated nervous system responds to life’s stressors with greater equanimity protecting long-term wellbeing.
The ExoMind™ Safety Advantage
What ExoMind™ Does Not Do
Is Just as Important
No Weight Gain
Unlike SSRIs and SNRIs, TMS has no metabolic effects. TMS has minimal systemic effects because treatment is delivered directly to targeted brain circuits.
No Memory Loss
TMS is not associated with memory loss. Cognitive sharpness is preserved and often improved.
No Sexual Side Effects
One of the most reported medication complaints entirely absent with TMS.
No Drug Interactions
TMS does not interfere with psychiatric or medical medications. Combine with your current regimen safely.
The Patient Experience
A Session That Fits
Your Life Completely
We designed the ExoMind™ experience around what patients told us they feared most disruption, loss of control, and clinical coldness. Every detail has been addressed.
Arriving for Your Session
You arrive at our private South Florida or Pembroke Pines clinic. No hospital wards, no intimidating equipment. You check in and settle into a private treatment suite designed for calm.
During the Session
You recline in a treatment chair with the TMS coil positioned against your scalp. You remain awake throughout treatment. Session duration depends on the prescribed protocol.
After Your Session
You stand up, collect your things, and leave. Drive yourself. Return directly to work. Exercise, social plans, normal life nothing is off-limits. Zero downtime. Every single time.
TREATMENT AT A GLANCE
Up to 36 sessions / FDA-Cleared MDD TMS
Fully awake /no sedation ever
You hold the pause / complete control
Generally 6–8 sessions / Accelerated off-label · Self-pay
Financing options may be available for eligible patients interested in accelerated self-pay ExoMind services. Financing is subject to approval, eligibility, and the financing provider’s terms.
Week 1–2
Adjustment period Brain acclimating
Week 2–3
First mood shifts Many patients notice
Week 4–5
Momentum builds Sleep often improves
Week 6–7
Significant change Energy & motivation
Week 9
Full course complete Outcomes assessed
The Patient Experience
Neuroplasticity at work
Before Exotms
During Exotms
After Exotms
Clinical Safety & Patient Trust
15 Years of Evidence.
An Exceptional Safety Record
ExoMind™ TMS is among the safest interventions in modern psychiatry. Here is what the clinical record shows.
Minimal Side Effect Profile
The most commonly reported side effect is mild scalp discomfort during early sessions — resolves spontaneously and diminishes after the first week. No systemic side effects.
PUBLISHED SAFETY DATA
Zero Cognitive Impact
Unlike ECT, TMS produces no seizures, no memory disruption, and no cognitive side effects. Patients frequently report improvements in concentration and mental clarity.
15+ YEARS POST-MARKET DATA
Medication Compatible
TMS can be administered safely alongside your current psychiatric medications. Our Psychiatric review your full medication list at evaluation and monitor throughout treatment.
PSYCHIATRIST-SUPERVISED
Global Clinical Validation
TMS has been used in tens of thousands of patients internationally across major medical centers — spanning multiple RCTs, meta-analyses, and 15+ years of registry data.
INTERNATIONAL EVIDENCE BASE
Compare ExoMind Treatment Pathways
Swipe horizontally to compare both pathways.
| Treatment details | FDA-Cleared MDD TMS | Accelerated ExoMind |
|---|---|---|
| Protocol | FDA-cleared protocol for major depressive disorder | Personalized accelerated off-label protocols |
| Session duration | Approximately 18–18:45 minutes per session at ACC | Approximately 24–30 minutes |
| Treatment course | Up to 36 sessions, depending on the prescribed course and clinical needs | Generally 6–8 sessions |
| Payment | May be covered by insurance for eligible patients | Self-pay / out-of-pocket |
| Financing | Ask ACC about payment options for any out-of-pocket costs | Financing options may be available for eligible patients |
Insurance coverage
Insurance coverage depends on plan-specific clinical criteria, medical necessity, benefits, prior authorization when required, and final insurance approval. Coverage is not guaranteed.
Accelerated ExoMind / Off-Label
Accelerated off-label services are separate from the FDA-cleared MDD insurance pathway. Off-label or wellness services should not be considered covered by insurance unless specifically authorized by the patient’s plan.
Self-Pay Financing
Financing options may be available for eligible patients interested in self-pay ExoMind services. Financing is subject to approval, eligibility, and the terms of the applicable financing provider.
Financing availability, approval, rates, terms, and monthly payment amounts are determined by the financing provider and may vary by applicant.
| ExoMind TMS | Standard TMS | Deep TMS | Medication | Therapy Alone | |
|---|---|---|---|---|---|
| Comfort |
Very Comfortable
|
Moderate Discomfort
|
Pressure
|
Side Effects
|
|
| Session Time |
~15–25 Mins
|
~30–40 Mins
|
20+ Mins
|
Daily Compliance
|
45+ Mins
|
| Speed of Results |
Faster
|
Gradual
|
Moderate
|
Delayed
|
Slow
|
| Personalization |
Highly Customizable
|
Limited
|
Limited
|
Trial/Error
|
Variable
|
| Side Effects |
Minimal
|
Headaches Common
|
Discomfort
|
Frequent
|
|
| Cognitive Boost |
Minimal
|
Limited
|
Limited
|
None
|
Indirect
|
Conditions We Treat
Beyond Depression Full Spectrum Neuromodulation
ExoMind™ utilizes FDA-cleared TMS technology for major depressive disorder, with expanding clinical evidence supporting applications in OCD, anxiety disorders, PTSD, bipolar depression, and other conditions.
⭐ FDA Cleared
Major Depression
The best-established clinical indication for TMS. Large clinical trials demonstrate meaningful improvements in depressive symptoms, including remission in a substantial proportion of patients. Proven effective when one or more antidepressants have failed. Targets the underactive dorsolateral prefrontal cortex. Published response rates of 50–60%, with ~30% achieving full remission.
⭐ FDA Cleared
OCD
Clinical evidence supports modulation of the anterior cingulate and medial prefrontal circuits involved in obsessive thoughts and compulsive behaviors. ExoMind™ protocols are individualized based on each patient’s presentation.
Evidence-Based
Anxiety Disorders
Generalized anxiety, panic disorder, and social anxiety, clinical studies suggest TMS may improve generalized anxiety, panic symptoms, and social anxiety by modulating prefrontal-limbic networks involved in fear regulation.
Emerging Evidence
PTSD
A growing body of clinical research supports TMS for post-traumatic stress disorder specialist protocols for veterans, first responders, and civilian trauma survivors.
Specialist Protocol
Bipolar Depression
Carefully selected patients with bipolar depression may benefit from individualized ExoMind™ protocols under close psychiatric supervision to reduce the risk of mood switching.
Research Supported
Smoking Cessation
Clinical studies suggest TMS may reduce nicotine cravings and support smoking cessation. Applications with ExoMind™ are individualized and considered off-label in the United States.
GROWING EVIDENCE
- ADHD
- Insomnia
- Chronic Pain
- Fibromyalgia
- Alcohol Use Disorder
- Smoking Cessation
- Cognitive Impairment
- Brain Fog
- Post-Concussion Symptoms
- Long COVID Cognitive Symptoms
Traumatic Brain Injury (TBI)
WELLNESS & PERFORMANCE
- Executive Function
- Mental Clarity
- Working Memory
- Focus
- Emotional Regulation
- Stress Resilience
- Burnout Recovery
- Cognitive Performance
- Mental Fatigue
- Peak Performance
- Healthy Aging
Some applications involve emerging or off-label uses of TMS and are considered individually following a comprehensive psychiatric evaluation.
Accelerated off-label and wellness services are a separate self-pay pathway from FDA-cleared MDD TMS. These services should not be considered covered by insurance unless specifically authorized by the patient’s plan.
Financing options may be available for eligible self-pay patients, subject to approval, eligibility, and the financing provider’s terms.
Our services
Comprehensive Mental Health Services Under One Roof
Common Questions
Everything You
Need to Know
We believe an informed patient is an empowered patient. These are the questions we hear most answered with clinical honesty and the directness you deserve.
Still have questions?
Our clinical team is available to answer your questions before you book.
Most individuals are potential candidates for ExoMind™, whether they are seeking support for a diagnosed mental health condition or looking to optimize emotional well-being, cognitive performance, or resilience. Every patient undergoes a comprehensive psychiatric evaluation to determine the safest and most appropriate personalized treatment plan.
The timing and degree of improvement vary by patient, clinical condition, and prescribed treatment protocol. Your provider will discuss treatment expectations during your evaluation and monitor your clinical response throughout your prescribed course. Results vary, and neither a specific outcome nor a timeline for improvement is guaranteed.
ACC now offers an FDA-cleared TMS pathway for major depressive disorder (MDD) that may be covered by medical insurance for eligible patients. Coverage depends on your plan’s clinical criteria, medical necessity, benefits, prior authorization when required, and final insurance approval. Coverage is not guaranteed.
Accelerated ExoMind and other off-label or wellness protocols are a separate self-pay pathway. These services should not be considered covered by insurance unless specifically authorized by your plan.
Financing options may be available for eligible patients interested in self-pay ExoMind services. Financing is subject to approval, eligibility, and the terms of the applicable financing provider.
Yes. Most patients continue their prescribed psychiatric and medical medications during ExoMind™ treatment. Your Psychiatric will review your complete medication regimen to ensure your treatment plan is safe and individualized.
Most patients describe a light tapping or knocking sensation on the scalp some compare it to a woodpecker-like rhythm. This sensation diminishes significantly after the first few sessions. No pain, no heat, no uncomfortable sensation inside the skull. Most patients describe a light tapping or rhythmic knocking sensation on the scalp during treatment. The sensation usually becomes less noticeable after the first few sessions. Patients remain awake, comfortable, and can return to normal activities immediately afterward.
After completing your prescribed ExoMind treatment course, your provider will review your clinical response and discuss follow-up care. Any maintenance sessions will be considered individually based on your clinical needs and response to treatment.
The FDA-cleared MDD pathway may include up to 36 sessions, depending on the prescribed treatment course and clinical needs. Personalized accelerated off-label protocols generally involve 6–8 sessions and are offered as a separate self-pay pathway.
Insurance coverage for additional treatment is subject to plan requirements and final insurance approval. Coverage is not guaranteed. Financing options may be available for eligible self-pay patients, subject to approval, eligibility, and the financing provider’s terms.
Yes. ACC offers telehealth psychiatric services throughout Florida, including evaluations, medication management, and follow-up appointments. ExoMind™ treatments are performed in person at our North Miami and Pembroke Pines locations.
Watch & Learn
Real Stories of Support, Care, and Progress
Hear from patients who have experienced compassionate mental health support, personalized care, and guidance designed to help them move forward with greater confidence and emotional well being.
Flexible Care Options
Insurance, Self-Pay & Financing
FDA-Cleared TMS for Major Depressive Disorder
TMS for major depressive disorder (MDD) may be covered by insurance for eligible patients. Coverage depends on plan-specific clinical criteria, medical necessity, benefits, prior authorization when required, and final insurance approval. Coverage is not guaranteed.
Accelerated ExoMind / Off-Label
Personalized accelerated ExoMind protocols are separate off-label, self-pay services. These services should not be considered covered by insurance unless specifically authorized by the patient’s plan.
Financing options may be available for eligible patients interested in self-pay ExoMind services. Financing is subject to approval, eligibility, and the terms of the applicable financing provider.
Financing availability, approval, rates, terms, and monthly payment amounts are determined by the financing provider and may vary by applicant.
Consultations Available This Week
Take the First Step
Toward Mental Clarity
Schedule a consultation with ACC’s psychiatric team to discuss which ExoMind pathway may be appropriate for you.
FDA-cleared TMS for major depressive disorder may be covered by insurance for eligible patients. Coverage depends on clinical eligibility, plan requirements, and final insurance approval. Coverage is not guaranteed.
Accelerated off-label ExoMind is a separate self-pay pathway. Financing options may be available for eligible patients, subject to approval, eligibility, and the financing provider’s terms.